# US 2019/0169612 A1 · Methods of Manipulating the Fate of Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169612 A1
- Document ID: US20190169612A1
- Status: Published application
- Kind: A1
- Application number: 16/031,529
- Filed: 2018-07-10
- Published: 2019-06-06
- Earliest claimed: 2001-06-22
- Inventors: Ivan Bergstein
- Web page: https://patentgrep.com/patent/US20190169612A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2320/30: Special therapeutic applications
- C12N 2320/31: Combination therapy
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method of manipulating the fate of a cell, which comprises contacting the cell with at least one of (a) a cell fate-determining untranslated/noncoding RNA species (cuR), (b) a modified cuR, or (c) a compound that modifies or affects cuR, under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. Another aspect of the invention relates to a method of manipulating the fate of a cell by contacting the cell with a compound that affects a fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA or RNA:DNA or resolution of such interactions under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. The invention generates cell fate or cell maintenance in a subject, such as a human, so that an increase of desirable cells or a decrease in undesirable cells can be obtained in the subject. This feature can be applied to a therapeutic method of treating a condition in a subject.

## Claims

### Claim 1

A method of increasing desirable cell population or decreasing undesirable cell population which comprises manipulating the fate of a cell through contact with a compound that affects a cell fate-determining mechanism involving RNA-silencing, RNA-interference, RNA-editing, snoRNA-mediated modifications, tRNA primed events, or other fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA, RNA:DNA, or DNA:DNA and their resolution under conditions to cause the cell to change or maintain fate, wherein the compound affects a cell-fate-determining untranslated/noncoding RNA species (cuR) associated protein, a cuR-associated riboprotein, or other nucleic acid, protein or riboprotein involved in the cell fate-determining mechanism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the change or maintenance of cell fate results in cell regeneration, cell differentiation, or cell death for applications involving regenerative biology, medicine, developmental biology, cancer, and aging.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell is a stem cell, regenerative cell, or a cancer cell and wherein the compound is naturally occurring, synthesized, or procured through a screen and comprises a nucleic acid, a protein, a riboprotein, a vaccine, a small molecule, or a chemical compound.

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound is identified through use of an assay in a screen of biological or chemical libraries of compounds.

### Claim 5 (depends on 3)

The method of claim 3, wherein the compound is intelligently designed.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is administered to a human in order to increase desirable cell population or decrease undesirable cell population therein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the compound is administered in combination with another related compound, or agent including chemotherapy, radiation, differentiation, immunotherapy, gene therapy, cancer therapy, or regenerative therapy.

### Claim 14 (depends on 13)

The method of claim 13, wherein the administration causes a level of toxicity which is clinically tolerable.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

A method of manipulating the fate of a cell, which comprises contacting the cell with a compound that modifies or affects a cell fate-determining untranslated/noncoding RNA species (cuR)-associated protein, a cuR-associated riboprotein, or other nucleic acid, protein or riboprotein involved in cell fate-determining mechanism involving RNA-silencing, RNA-interference, RNA-editing, snoRNA-mediated modifications, tRNA primed events, or other fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA, RNA:DNA, or DNA:DNA and their resolution under conditions to cause the cell to change or maintain fate, under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the protein or riboprotein is:
(a) a RdRp-like protein or riboprotein;
(b) a eIF2C-like protein or riboprotein;
(c) a RNase D-like protein or riboprotein;
(d) piwi;
(e) hiwi;
(f) RNA component of the riboprotein RNase MRP (RMRP); or
(g) an RNA-editing-related protein.

### Claim 23 (depends on 22)

The method of claim 22, wherein the RdRp-like protein or riboprotein of (a) is qde1, sg2, or ego1.

### Claim 24 (depends on 22)

The method of claim 22, wherein the eIF2C-like protein or riboprotein of (b) is qde2, rde1, or a RecQ-like protein or riboprotein.

### Claim 25 (depends on 24)

The method of claim 24, wherein the RecQ-like protein or riboprotein is qde3.

### Claim 26 (depends on 22)

The method of claim 22, wherein the RNase D-like protein or riboprotein of (c) is mut7.

### Claim 27 (depends on 22)

The method of claim 22, wherein the RNA-editing-related protein is an adenosine deaminase (ADAR).

### Claim 28 (depends on 17)

The method of claim 17, wherein the protein or riboprotein is:
(a) a RdRp-like protein or riboprotein;
(b) a eIF2C-like protein or riboprotein;
(c) a RNase D-like protein or riboprotein;
(d) piwi;
(e) hiwi;
(f) RNA component of the riboprotein RNase MRP (RMRP); or
(g) an RNA-editing-related protein.

### Claim 29 (depends on 28)

The method of claim 28, wherein the RdRp-like protein or riboprotein of (a) is qde1, sg2, or ego1.

### Claim 30 (depends on 28)

The method of claim 28, wherein the eIF2C-like protein or riboprotein of (b) is qde2, rde1, or a RecQ-like protein or riboprotein.

### Claim 31 (depends on 30)

The method of claim 30, wherein the RecQ-like protein or riboprotein is qde3.

### Claim 32 (depends on 28)

The method of claim 28, wherein the RNase D-like protein or riboprotein of (c) is mut7.

### Claim 33 (depends on 28)

The method of claim 28, wherein the RNA-editing-related protein is adenosine deaminase (ADAR).
